S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
NASDAQ:SRRK

Scholar Rock - SRRK Stock Forecast, Price & News

$9.09
+0.57 (+6.69%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$8.18
$9.56
50-Day Range
$4.66
$8.92
52-Week Range
$4.32
$44.95
Volume
598,055 shs
Average Volume
769,221 shs
Market Capitalization
$320.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.14

Scholar Rock MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
220.6% Upside
$29.14 Price Target
Short Interest
Healthy
7.34% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.74
Upright™ Environmental Score
News Sentiment
-0.74mentions of Scholar Rock in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$5.87 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.48) to ($2.69) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

405th out of 1,098 stocks

Biological Products, Except Diagnostic Industry

65th out of 174 stocks

SRRK stock logo

About Scholar Rock (NASDAQ:SRRK) Stock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Scholar Rock Stock Up 6.7 %

NASDAQ:SRRK traded up $0.57 during midday trading on Tuesday, reaching $9.09. 595,955 shares of the stock traded hands, compared to its average volume of 769,203. Scholar Rock has a 12-month low of $4.32 and a 12-month high of $44.95. The business has a 50-day moving average of $6.52 and a two-hundred day moving average of $10.28. The company has a debt-to-equity ratio of 0.25, a quick ratio of 6.85 and a current ratio of 6.85. The stock has a market capitalization of $320.90 million, a PE ratio of -3.02 and a beta of 0.63.

Scholar Rock (NASDAQ:SRRK - Get Rating) last posted its earnings results on Monday, August 8th. The company reported ($1.06) EPS for the quarter, missing analysts' consensus estimates of ($1.04) by ($0.02). Scholar Rock had a negative net margin of 236.95% and a negative return on equity of 59.99%. The firm had revenue of $1.00 million for the quarter. During the same period last year, the firm earned ($0.84) earnings per share. The firm's revenue was down 78.2% compared to the same quarter last year. On average, equities analysts forecast that Scholar Rock will post -2.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. JPMorgan Chase & Co. reduced their target price on shares of Scholar Rock from $46.00 to $37.00 in a report on Tuesday, May 24th. BMO Capital Markets cut their price target on shares of Scholar Rock from $55.00 to $43.00 in a report on Tuesday. Wedbush cut their price target on shares of Scholar Rock from $50.00 to $33.00 and set a "na" rating on the stock in a report on Tuesday, May 17th. Piper Sandler lowered their price target on shares of Scholar Rock from $28.00 to $19.00 and set an "overweight" rating for the company in a research report on Thursday, June 23rd. Finally, Truist Financial started coverage on shares of Scholar Rock in a research report on Tuesday, July 12th. They issued a "buy" rating and a $20.00 price target for the company. One equities research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $29.14.

Insider Buying and Selling at Scholar Rock

In related news, Director Amir Nashat purchased 1,197,992 shares of the business's stock in a transaction on Wednesday, June 22nd. The shares were acquired at an average price of $4.90 per share, for a total transaction of $5,870,160.80. Following the purchase, the director now owns 3,540,530 shares of the company's stock, valued at approximately $17,348,597. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.05% of the stock is currently owned by company insiders.

Receive SRRK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scholar Rock and its competitors with MarketBeat's FREE daily newsletter.

SRRK Stock News Headlines

5 Analysts Have This to Say About Scholar Rock Holding
Where Scholar Rock Holding Stands With Analysts
Why Scholar Rock Shares Are Trading Higher Today
What 4 Analyst Ratings Have To Say About Scholar Rock Holding
See More Headlines
Receive SRRK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scholar Rock and its competitors with MarketBeat's FREE daily newsletter.

SRRK Company Calendar

Last Earnings
8/08/2022
Today
8/09/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SRRK
Employees
145
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$29.14
High Stock Price Forecast
$43.00
Low Stock Price Forecast
$19.00
Forecasted Upside/Downside
+220.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-131,800,000.00
Net Margins
-236.95%
Pretax Margin
-236.95%

Debt

Sales & Book Value

Annual Sales
$18.82 million
Book Value
$4.90 per share

Miscellaneous

Free Float
34,578,000
Market Cap
$320.90 million
Optionable
Not Optionable
Beta
0.63

Key Executives

  • Dr. Nagesh K. Mahanthappa MBA (Age 57)
    Ph.D., Interim CEO, Pres & Director
    Comp: $356.22k
  • Mr. Edward H. Myles M.B.A. (Age 50)
    MBA, CFO, COO & Treasurer
    Comp: $615.87k
  • Dr. Gregory John Carven Ph.D. (Age 46)
    Chief Scientific Officer
  • Ms. Catherine Hu
    VP of Investor Relations & Corp. Communications
  • Ms. Junlin Ho J.D. (Age 43)
    Gen. Counsel & Corp. Sec.
  • Ms. Caryn Parlavecchio (Age 50)
    Chief HR Officer
  • Ms. Lisa Amaya Price
    Sr. VP of HR
  • Dr. George G. Nomikos M.D.
    Ph.D., Sr. VP of Medical & Clinical Sciences and Head of Muscle Therapeutic Area
  • Ms. Erin Moore (Age 47)
    Sr. VP of Fin.
  • Mr. Ryan Iarrobino
    Sr. VP of Clinical Devel. & Operations













SRRK Stock - Frequently Asked Questions

Should I buy or sell Scholar Rock stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SRRK shares.
View SRRK analyst ratings
or view top-rated stocks.

What is Scholar Rock's stock price forecast for 2022?

4 analysts have issued 12-month price targets for Scholar Rock's stock. Their SRRK share price forecasts range from $19.00 to $43.00. On average, they anticipate the company's share price to reach $29.14 in the next twelve months. This suggests a possible upside of 219.5% from the stock's current price.
View analysts price targets for SRRK
or view top-rated stocks among Wall Street analysts.

How has Scholar Rock's stock performed in 2022?

Scholar Rock's stock was trading at $24.84 at the beginning of 2022. Since then, SRRK stock has decreased by 63.3% and is now trading at $9.12.
View the best growth stocks for 2022 here
.

When is Scholar Rock's next earnings date?

Scholar Rock is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our SRRK earnings forecast
.

How were Scholar Rock's earnings last quarter?

Scholar Rock Holding Co. (NASDAQ:SRRK) released its quarterly earnings data on Monday, August, 8th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.04) by $0.02. The business had revenue of $1 million for the quarter. Scholar Rock had a negative trailing twelve-month return on equity of 59.99% and a negative net margin of 236.95%. Scholar Rock's revenue was down 78.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.84) earnings per share.

What other stocks do shareholders of Scholar Rock own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Scholar Rock investors own include Fulcrum Therapeutics (FULC), Coherus BioSciences (CHRS), CTI BioPharma (CTIC), Exelixis (EXEL), GlycoMimetics (GLYC), Nektar Therapeutics (NKTR), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV) and Atara Biotherapeutics (ATRA).

When did Scholar Rock IPO?

(SRRK) raised $76 million in an initial public offering on Thursday, May 24th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Scholar Rock's stock symbol?

Scholar Rock trades on the NASDAQ under the ticker symbol "SRRK."

Who are Scholar Rock's major shareholders?

Scholar Rock's stock is owned by many different retail and institutional investors. Top institutional investors include TD Asset Management Inc. (0.40%), Swiss National Bank (0.24%), Rice Hall James & Associates LLC (0.14%), SG Americas Securities LLC (0.07%), Lazard Asset Management LLC (0.03%) and Denali Advisors LLC (0.02%). Insiders that own company stock include Amir Nashat, Edward H Myles, Gregory John Carven, Jeffrey S Flier and Michael Gilman.
View institutional ownership trends
.

How do I buy shares of Scholar Rock?

Shares of SRRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Scholar Rock's stock price today?

One share of SRRK stock can currently be purchased for approximately $9.12.

How much money does Scholar Rock make?

Scholar Rock (NASDAQ:SRRK) has a market capitalization of $321.94 million and generates $18.82 million in revenue each year. The company earns $-131,800,000.00 in net income (profit) each year or ($3.04) on an earnings per share basis.

How many employees does Scholar Rock have?

Scholar Rock employs 145 workers across the globe.

How can I contact Scholar Rock?

Scholar Rock's mailing address is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. The official website for the company is www.scholarrock.com. The company can be reached via phone at (857) 259-3860, via email at chu@scholarrock.com, or via fax at 866-493-4935.

This page (NASDAQ:SRRK) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.